Elegen and Nutcracker Therapeutics to Pilot First Fully Cell-Free Manufacturing Process
for RNA-based Personalized Cancer Therapeutics
SOURCE: Business Wire
JUL 11, 2025
Fully cell-free process aims to further democratize personalized cancer therapeutic manufacturing with shorter turnaround times and negligible bioburden and endotoxin risks.
